Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting PRESS RELEASE Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Overall survival benefit from tebentafusp in patients with best...

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting  PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual...

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp in unresectable or metastatic uveal...

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting OXFORDSHIRE, England and CONSHOHOCKEN, Penn. and ROCKVILLE, Md., March 10, 2021 (GLOBE NEWSWIRE) -- Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a...

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel...